[1]杨正勤*,王小玉,李睿,等.血清miR-93在子宫内膜癌中的表达及临床意义[J].中国计划生育和妇产科,2020,(1):73-77.
　YANG Zheng-qin*,WANG Xiao-yu,LI Rui,et al.Expression of serum miR-93 in endometrial carcinoma and its clinical significance[J].Chinese Journal of Family Planning & Gynecotokology,2020,(1):73-77.
点击复制

血清miR-93在子宫内膜癌中的表达及临床意义
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2020年1期
页码:
73-77
栏目:
论著与临床
出版日期:
2020-01-25

文章信息/Info

Title:
Expression of serum miR-93 in endometrial carcinoma and its clinical significance
作者:
杨正勤1*; 王小玉1; 李睿1; 徐国蕊2; 李梅2
安徽医科大学附属六安医院,1.妇产科；2.病理科
Author(s):
YANG Zheng-qin1*; WANG Xiao-yu1; LI Rui1; XU Guo-rui2; LI Mei2
1.Department of Obstetrics and Gynecology;2.Department of Pathology, Lu'an Hospital Affiliated to Anhui Medical University, Lu'an Anhui 237000, P.R.China
关键词:
子宫内膜癌; miR-93; 诊断; 淋巴结转移; 糖类抗原125; 人附睾分泌蛋白E 4
Keywords:
endometrial cancer;  miR-93;  diagnosis;  lymph node metastasis;  carbohydrate antigen 125;  human epididymis secretory protein E4
分类号:
R 737.33
摘要:
目的探讨血清miR-93在子宫内膜癌（endometrial carcinoma，EC）中的表达及其临床意义。方法选取2016年10月至2018年12月在安徽医科大学附属六安医院接受治疗的EC患者133例作为EC组，同期接受治疗的子宫良性疾病患者87例作为良性对照组，同期在我院体检的健康志愿者82例作为健康对照组。比较3组研究对象血清miR-93、糖类抗原125（carbohydrate antigen 125，CA 125）、人附睾分泌蛋白 E 4（human epididymal secretory protein E 4，HE 4）的水平，分析其血清水平与EC患者临床病理特征之间的关系，以及对EC的早期诊断及淋巴结转移预测的价值。结果EC组的血清miR-93、CA 125、HE 4水平高于良性对照组和健康对照组（P<005）。EC患者血清miR-93水平与FIGO分期、分化程度、肌层浸润深度、淋巴结转移有关（P<005）；EC患者血清CA 125水平与FIGO分期、肌层浸润深度、淋巴结转移有关（P<005）；EC患者血清HE 4水平与年龄、FIGO分期、肌层浸润深度、淋巴结转移有关（P<005）；血清miR-93对EC有较高的早期诊断价值及淋巴结转移预测价值，且在与CA 125、HE 4联合检测后，对EC的早期诊断价值及淋巴结转移预测价值将会得到进一步提升。结论miR-93在EC患者血清中呈高表达，且与FIGO分期、分化程度、肌层浸润深度、淋巴结转移有关，对EC有较高的早期诊断价值及淋巴结转移预测价值，联合CA 125、HE 4可进一步提高其临床应用价值。
Abstract:
ObjectiveTo investigate the expression and clinical significance of serum miR-93 in endometrial cancer(EC). MethodsFrom October 2016 to December 2018, 133 patients with EC who were treated at Lu'an Hospital Affiliated to Anhui Medical University were selected as the EC group, 87 patients with benign uterine diseases who were treated in the same period were used as benign control group, and 82 healthy volunteers who were examined in our hospital during the same period were used as healthy control group. The levels of serum miR-93, carbohydrate antigen 125 (CA 125) and human epididymal secretory protein E 4 (HE 4) were compared between the three groups. The serum levels were analyzed between the clinician and the clinicopathological features of EC patients. The relationship, as well as its value for early diagnosis of EC and prediction of lymph node metastasis. ResultsSerum levels of miR-93, CA 125 and HE 4 in the EC group were higher than those in the benign control group and the healthy control group (P<005). Serum miR-93 levels in EC patients were associated with FIGO stage, degree of differentiation, depth of myometrial invasion, and lymph node metastasis (P<005). Serum CA 125 levels in EC patients were associated with FIGO stage, depth of myometrial invasion, and lymph node metastasis (P<005). Serum HE 4 levels in EC patients were associated with age, FIGO stage, depth of myometrial invasion, and lymph node metastasis (P<005). Serum miR-93 had a higher early diagnostic value and predictive value of lymph node metastasis, and was associated with CA 125. After combined detection of HE 4, the value of early diagnosis of EC and the predictive value of lymph node metastasis will be further improved. ConclusionmiR-93 is highly expressed in the serum of EC patients, and is associated with FIGO stage, differentiation degree, depth of myometrial invasion and lymph node metastasis. It has high early diagnostic value and predictive value of lymph node metastasis. It can be combined with CA 125 and HE 4 to further improve its clinical application value.

参考文献/References:

［1］JEPPESEN M M, MOGENSEN Ole, HANSEN D G, et al. Detection of recurrence in early stage endometrial cancer - the role of symptoms and routine follow-up ［J］. Acta Oncologica (Stockholm, Sweden), 2017, 56(2): 262-269. ［2］刘从容，孙耘田．子宫内膜癌筛查和早期诊断专家共识(草案) ［J］．中国实用妇科与产科杂志，2017，33（10）：1050-1052． ［3］冯小丹．预测子宫内膜癌患者腹主动脉旁淋巴结转移方法的研究进展 ［J］．国际妇产科学杂志，2018，45（2）：207-211． ［4］罗燕红，谢鹏，何侠，等．血清miR-93在乳腺癌患者早期诊断和术后评估中的作用 ［J］．南京医科大学学报（自然科学版），2015，35（9）：1235-1237． ［5］李佳一，吴双，范丽菲，等．血清miR-93含量与卵巢癌相关性研究 ［J］．中国细胞生物学学报，2017，39（7）：857-864． ［6］周赞华，董海娜，朱莉，等．miR-93在子宫内膜癌中的表达及意义 ［J］．中国妇幼保健，2015，30（12）：1925-1927． ［7］周琦，吴小华，刘继红，等．子宫内膜癌诊断与治疗指南 ［J］．中国实用妇科与产科杂志，2018，34（8）：880-886． ［8］WANG Yingmei, HAN Cha, TENG Fei, et al. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer ［J］. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2017, 136(1): 58-63. ［9］DONG Chunhua, LIU Ping, LI Chao. Value of HE4 combined with cancer antigen 125 in the diagnosis of endometrial cancer ［J］. Pakistan Journal of Medical Sciences, 2017, 33(4): 1013-1017. ［10］BRENNAN D J, HACKETHAL A, METCALF A M, et al. Serum HE4 as a prognostic marker in endometrial cancer - A population based study ［J］. Gynecologic Oncology, 2014, 132(1): 159-165. ［11］熊焱强，李志英．循环miRNA在妇科肿瘤早期筛查及诊断中的研究进展 ［J］．现代妇产科进展，2015，24（6）：469-471． ［12］刘更，周鸿鹰．miR-93与肿瘤的研究进展 ［J］．四川解剖学杂志，2013，21（3）：28-31． ［13］蔡静清，王宁，张敏．非小细胞肺癌血浆miR-223、miR-93和miR-218的表达及其临床意义［J］．临床肿瘤学杂志，2014，19（12）：1075-1080． ［14］马志军，马玉兰，夏清华，等．微小RNA-93在胃癌中的表达及其在体外对AGS细胞生长的影响 ［J］．中华实验外科杂志，2016，33（2）：299-302． ［15］CHEN Shuo, CHEN Xi, SUN Kai-xuan, et al. MicroRNA-93 promotes Epithelial-Mesenchymal transition of endometrial carcinoma cells ［J］. PLOS One, 2016, 11(11): e 0165776. ［16］赵智凝，刘楠，赵晓余，等．miR-106b-93-25簇对子宫内膜癌细胞的调控作用研究 ［J］．现代生物医学进展，2015，15（25）：4842-4847． ［17］张云鹤．抑癌基因PTEN与妇科肿瘤研究进展 ［J］．北京医学，2017，39（4）：390-392, 395． ［18］OHTA K, HOSHINO H, WANG Jinhua, et al. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A ［J］. Oncotarget, 2015, 6(5): 3211-3224. ［19］LI Nan-a, MIAO Yuan, SHAN Yu-jia, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer ［J］. Cell Death & Disease, 2017, 8(5): e 2796. ［20］朱瑜苑，谢咏，徐冰南，等．腹腔镜吲哚菁绿荧光显影指引淋巴结切除用于早期子宫内膜癌分期手术的临床研究 ［J］．中国实用妇科与产科杂志，2018，34（10）：85-90． ［21］林仲秋，谢玲玲，林荣春．《2016 NCCN子宫肿瘤临床实践指南》解读 ［J］．中国实用妇科与产科杂志，2016，33（2）：117-122．

相似文献/References:

[1]胡玲,胡健蓉,徐凤仪,等.血管内皮生长因子在子宫内膜癌中的表达及其意义[J].中国计划生育和妇产科,2011,(01):0.
　HU Ling,HU Jian-rong,XU Feng-yi,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[2]孙红敏,苑中甫.胰岛素样生长因子受体-1在子宫内膜癌组织中的表达及意义[J].中国计划生育和妇产科,2011,(02):0.
　SUN Hong-min,WAN Zhong-fu ..[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[3]田兆华,王建六.应客观评价腹膜后淋巴结切除在子宫内膜癌的治疗价值[J].中国计划生育和妇产科,2011,(03):0.
[4]陈晓丽.CD44v6、MMP-2在子宫内膜癌的表达及临床意义[J].中国计划生育和妇产科,2011,(03):0.
　CHEN Xiao-li.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(1):0.
[5]梅彤,舒宽勇.CD133在子宫内膜癌中的研究进展[J].中国计划生育和妇产科,2012,(04):0.
　MEI Tong,SHU Kuan-yong* .Medical.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(1):0.
[6]曹晓智,王小捷,李凤山,等.宫内膜细胞p16基因表达检测筛查子宫内膜癌的研究[J].中国计划生育和妇产科,2013,(06):0.
　Cao Xiao-zhi,Wang Xiao-jie,Li Feng-shan,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(1):0.
[7]廖娟,杨菊生,李越,等.磁共振成像在Ⅰ、Ⅱ期子宫内膜癌术前分期中的应用分析[J].中国计划生育和妇产科,2014,(06):0.
　LIAO Juan,YANG Ju-sheng,LI Yue,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(1):0.
[8]姜志欣,吴玉璘.女性人乳头瘤病毒感染及相关肿瘤[J].中国计划生育和妇产科,2014,(07):0.
[9]魏丽惠.关于子宫内膜癌筛查的思考[J].中国计划生育和妇产科,2015,(01):0.
[10]张超,蒋国庆.子宫内膜癌细胞学筛查的Meta分析[J].中国计划生育和妇产科,2015,(06):0.
　ZHANG Chao,JIANG Guo-qing,[J].Chinese Journal of Family Planning & Gynecotokology,2015,(1):0.

备注/Memo

备注/Memo:
2016年安徽省卫生和计划生育委员会科研计划项目（项目编号：2016QH007）
更新日期/Last Update: 2020-01-25